BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Hemophilia clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for hemophilia: 90 (29 sponsors; 13 newly posted in the last 180 days, 7 stopped in the last 180 days; 3 new-entrant sponsors). Momentum score 27.2, rank 7 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 5, Phase 2 11, Phase 3 37, Phase 4 7, N/A 30.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Pfizer PFE | 9 | NA 2, P3 6, P1 1 | 2 | 1 |
| Novo Nordisk A/S NVO | 14 | NA 8, P3 5, P1 1 | 2 | 3 |
| Hoffmann-La Roche | 7 | P3 4, P2 2, P4 1 | 1 | 1 |
| Suzhou Alphamab Co., Ltd. | 4 | P3 3, P2 1 | 0 | 0 |
| Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 3 | P3 3 | 2 | 3 |
| Sanofi SNY | 7 | P4 2, NA 3, P3 2 | 1 | 1 |
| CSL Behring | 5 | P3 2, NA 3 | 0 | 0 |
| Shanghai Xinzhi BioMed Co., Ltd. | 2 | P3 2 | 0 | 0 |
| Biocad | 3 | P2 2, P3 1 | 0 | 1 |
| Swedish Orphan Biovitrum | 3 | P4 2, P3 1 | 0 | 1 |
| BioMarin Pharmaceutical BMRN | 2 | NA 1, P3 1 | 0 | 0 |
| Gritgen Therapeutics Co., Ltd. | 2 | P2 1, P3 1 | 0 | 1 |
| Shanghai RAAS Blood Products Co., Ltd. new entrant | 2 | P3 1, P2 1 | 2 | 1 |
| Sinocelltech Ltd. | 2 | P3 1, P1 1 | 1 | 0 |
| Bioverativ, a Sanofi company | 1 | P3 1 | 0 | 1 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Jiangsu BioJeTay Biotechnology Co., Ltd. | 1 | P3 1 | 0 | 0 |
| SK Plasma Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Bayer | 6 | NA 6 | 0 | 3 |
| Octapharma | 3 | NA 1, P4 2 | 0 | 2 |
| Baxalta now part of Shire | 2 | NA 1, P2 1 | 0 | 0 |
| Regeneron Pharmaceuticals REGN | 2 | P2 1, NA 1 | 0 | 1 |
| Takeda TAK | 2 | NA 2 | 0 | 0 |
| Arditus Pte Ltd new entrant | 1 | P2 1 | 1 | 1 |
| AryoGen Pharmed Co. new entrant | 1 | NA 1 | 1 | 1 |
New-entrant sponsors: Shanghai RAAS Blood Products Co., Ltd., Arditus Pte Ltd, AryoGen Pharmed Co..
Recently stopped trials
- NCT04046848 Octapharma - terminated: Study was terminated due to SADRs Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A
- NCT03307980 Pfizer - terminated: The study was terminated early due to Sponsor and participants may transition into a long-term follow-up study. The decision to terminate th Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B
- NCT00555555 Grifols Biologicals, LLC - terminated: Due to recruitment challenges during the trial, this study was terminated early by the Sponsor. Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients
- NCT04628871 Sangamo Therapeutics - terminated: Sangamo declared Chapter 11 Bankruptcy on 23Jun2026 and terminated the study on 21Jul2026. Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
- NCT05164471 Spur Therapeutics - terminated: Freeline has decided to pause development of FLT180a for business priorities Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B
- NCT05695391 Laboratoire français de Fractionnement et de Biotechnologies - terminated: Feasibility considerations - extended timelines to complete recruitment Safety and Efficacy of FVIIa to Prevent Excessive Bleeding in Hemophilia Patients With Inhibitors Undergoing Major Surge
- NCT06611436 Be Biopharma - terminated: The study was terminated due to a strategic business decision and not due to safety concerns BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P3 | Gritgen Therapeutics Co., Ltd. | NCT06833983 To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A | Hemophilia A | recruiting | 50 |
| 2026-12-31 est. | P3 | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | NCT06136507 Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A | Severe Hemophilia A | not yet recruiting | 76 |
| 2026-12-31 est. | P1/P2 | Shanghai RAAS Blood Products Co., Ltd. | NCT07644832 An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics | Hemophilia A; Hemophilia B; Factor VII Deficiency | recruiting | 76 |
| 2027-01-15 est. | P3 | Bioverativ, a Sanofi company | NCT04644575 Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A | Hemophilia A | active not recruiting | 261 |
| 2027-02 est. | P3 | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | NCT07663903 Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment | Severe Hemophilia A | active not recruiting | 60 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-15 est. | P3 | Suzhou Alphamab Co., Ltd. | NCT06569108 Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors | Hemophilia A Without Inhibitor; Hemophilia B Without Inhibitor | active not recruiting | 125 |
| 2026-09-23 | P3 | CSL Behring | NCT06738485 Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products | Congenital Hemophilia A | completed | 62 |
| 2026-09-15 | P1/P2 | Bayer | NCT03588299 Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy | Hemophilia A | completed | 11 |
| 2026-09-14 | P3 | Genzyme, a Sanofi Company | NCT03754790 Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX | Hemophilia | completed | 281 |
| 2026-09-02 est. | P2 | Suzhou Alphamab Co., Ltd. | NCT06747416 KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors | Hemophilia a and B | not yet recruiting | 24 |
| 2026-09 est. | P3 | Jiangsu BioJeTay Biotechnology Co., Ltd. | NCT06922045 Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients | Hemophilia | active not recruiting | 40 |
| 2026-08-04 | P2/P3 | Genzyme, a Sanofi Company | NCT03974113 Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B | Hemophilia | completed | 32 |
| 2026-07-31 est. | P3 | SK Plasma Co., Ltd. | NCT06738901 An Open-label Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SKP-0141 for the Treatment and Prophylaxis in Severe Hemophilia a P | Hemophilia A, Severe | not yet recruiting | 55 |
| 2026-07-23 | P2 | Pfizer PFE | NCT03307980 Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B | Hemophilia B | terminated | 21 |
| 2026-07-07 | P3 | CSL Behring | NCT06399289 Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy | Hemophilia B | completed | 23 |
| 2026-07 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT06297655 A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A | Hemophilia A | active not recruiting | 60 |
| 2026-06-02 | P3 | Swedish Orphan Biovitrum | NCT05817812 A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa | Hemophilia A, Severe | completed | 93 |
| 2026-05-29 | P1/P2 | Be Biopharma | NCT06611436 BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B | Hemophilia B; Hemophilia B, Moderately Severe or Severe | terminated | 5 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "hemophilia"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.